Released Nov 3, 2021, before the open
10-Q filed Nov 5, 2021, 36 days after period end · 0001171843-21-007633
Q3 2021 · 10-Q
Revenue$29.66M$29.66M +23.4% vs Q3 2020+1.6% vs Q2 2021
Net Income-$170.00K-$170.00K N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted$0.00$0.00 N/M vs Q3 2020N/M vs Q2 2021
Gross Profit$16,308,000+20.8%
Operating Income$548,000+201.1%
Operating Cash Flowderived-$660,000N/M
Free Cash Flowderived-$1,140,000N/M
Margins · derived
Gross margin55.0%−1.2 pt vs Q3 2020
Operating margin1.8%+1.1 pt vs Q3 2020
Net margin-0.6%+4.0 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $29.66M | $24.04M | $27.42M | $28.64M |
| Net Income | -$170.00K | -$1.10M | -$2.62M | -$256.00K |
| EPS Diluted | $0.00 | -$0.03 | -$0.07 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR